Effector mechanisms of IgA antibodies against CD20

CD 20抗体利妥昔单抗对不同类型B细胞淋巴瘤患者的生存率有显著改善。预计在不久的将来，新抗体的批准将取得更多进展。就其作用机制而言，CD 20抗体可分为两种不同类型：I型抗体在介导补体依赖性细胞毒性（CDC）方面有效，而II型抗体在触发肿瘤细胞凋亡方面特别有效。作为人IgG 1抗体，这两种类型的分子都能够募集NK细胞和单核细胞/巨噬细胞用于抗体依赖性细胞毒性（ADCC）。我们自己先前的工作已经证明，人IgG 1抗体-特别是当它们被工程化以实现对Fc γ RIII（CD 16）的更高亲和力时-不通过粒细胞操纵ADCC。然而，粒细胞特别好地被人伊加同种型的抗体激活。天然伊加抗体构成粘膜免疫系统的一个组成部分，但其作为治疗试剂在肿瘤免疫治疗中的作用尚未得到充分解决。最近，我们建立了生产和纯化技术，以产生足够量的重组人伊加抗体。在拟定项目中，选择I型（利妥昔单抗和奥法木单抗）和II型（obinutuzumab）CD 20抗体的可变区应作为IgA 1和IgA 2分子生产。然后将这些抗体与其各自的IgG 1分子在体外和体内进行功能比较。这些实验的结果将提高我们对CD 20抗体的相关作用机制的理解，并支持改进试剂的开发。此外，我们期待对伊加抗体的免疫抑制潜力的新见解。

The CD20 antibody rituximab has significantly contributed to the improved survival of patients with different types of B cell lymphomas. Additional progress is expected in the near future from the approval of novel antibodies. With respect to their mechanisms of action, CD20 antibodies can be grouped into two different types: type I antibodies are efficient in mediating complement dependent cytotoxicity (CDC), while type II antibodies are particularly efficient in triggering tumor cell apoptosis. As human IgG1 antibodies, both types of molecules are able to recruit NK cells and monocytes/macrophages for antibody-dependent cellular cytotoxicity (ADCC). Our own previous work has demonstrated that human IgG1 antibodies - particularly when they were engineered to achieve higher affinity for FcgammaRIII (CD16) - do not rigger ADCC by granulocytes. However, granulocytes are particularly well activated by antibodies of human IgA isotypes. Natural IgA antibodies constitute an integral part of the mucosal immune system, but their role as therapeutic reagents in tumor immunotherapy has not been adequately addressed. Recently, we established production and purification technologies to generate sufficient amounts of recombinant human IgA antibodies. Within the proposed project variable regions of select type I (rituximab and ofatumumab) and type II (obinutuzumab) CD20 antibodies shall be produced as IgA1 and IgA2 molecules. These antibodies shall then be functionally compared to their respective IgG1 molecules in vitro and in vivo. Results of these experiments shall improve our understanding of the relevant mechanisms of action of CD20 antibodies and support the development of improved reagents. Additionally, we expect novel insights into the immunotherapeutic potential of IgA antibodies.